Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mind Medicine (DE:MMQ)
FRANKFURT:MMQ
Holding DE:MMQ?
Track your performance easily
MMQ Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€2.22 - €12.03
Previous Close€7.69
Volume1.42K
Average Volume (3M)742.00
Market Cap
€565.18M
Enterprise Value€341.54M
Total Cash (Recent Filing)$252.33M
Total Debt (Recent Filing)$14.19M
Price to Earnings (P/E)―
Beta1.34
Next Earnings
Apr 08, 2025EPS Estimate
-€0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding81,430,000
10 Day Avg. Volume937
30 Day Avg. Volume742
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-9.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-3.65
Forecast
1Y Price Target
€23.53Price Target Upside205.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Mind Medicine News
PremiumCompany Announcements
Mind Medicine Set to Engage at Key Investor Conferences
PremiumCompany Announcements
MindMed Advances Phase 3 Trials in Mental Health
PremiumCompany Announcements
Mind Medicine’s Financial Health and Phase 3 Progress
PremiumCompany Announcements
MindMed Issues New Employee Share OptionsBulls Say, Bears Say
Bulls Say
Clinical TrialsThere is a high probability of success for MM120 in GAD, considering the strong phase 2 results announced earlier this year.
Financial PerformanceThe company ended 2Q24 with approximately $240M of cash, along with a recent $75M equity raise, extending the cash runway into 2027.
Regulatory PathFDA recently granted Breakthrough Therapy Designation to MM120, reducing regulatory risk.
Bears Say
Clinical ConductClinical conduct concerns related to psychotherapy, as well as concerns/risk related to the lack of standardization of active treatment sessions, have raised some concerns for other psychedelic products including MM120.
Evidence Report IssuesICER’s initial draft evidence report pointed to multiple concerns and controversies related to Lykos’ MDMA-assisted therapy, including functional unblinding and bias.
Regulatory ConcernsFDA had also asked Lykos to collect more data on AEs and abuse potential during phase 3, which wasn't captured to FDA's satisfaction.
---
Options Prices
Currently, No data available
---
Ownership Overview
2.52% Insiders
5.09% Mutual Funds
0.35% Other Institutional Investors
83.89% Public Companies and
Individual Investors
MMQ FAQ
What was Mind Medicine’s price range in the past 12 months?
Mind Medicine lowest stock price was €2.22 and its highest was €12.03 in the past 12 months.
What is Mind Medicine’s market cap?
Currently, no data Available
When is Mind Medicine’s upcoming earnings report date?
Mind Medicine’s upcoming earnings report date is Apr 08, 2025 which is in 146 days.
How were Mind Medicine’s earnings last quarter?
Mind Medicine released its earnings results on Nov 07, 2024. The company reported -€0.169 earnings per share for the quarter, beating the consensus estimate of -€0.26 by €0.091.
Is Mind Medicine overvalued?
According to Wall Street analysts Mind Medicine’s price is currently Undervalued.
Does Mind Medicine pay dividends?
Mind Medicine does not currently pay dividends.
What is Mind Medicine’s EPS estimate?
Mind Medicine’s EPS estimate is -€0.29.
How many shares outstanding does Mind Medicine have?
Mind Medicine has 73,331,690 shares outstanding.
What happened to Mind Medicine’s price movement after its last earnings report?
Mind Medicine reported an EPS of -€0.169 in its last earnings report, beating expectations of -€0.26. Following the earnings report the stock price went up 29.865%.
Which hedge fund is a major shareholder of Mind Medicine?
Currently, no hedge funds are holding shares in DE:MMQ
---
Mind Medicine Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€23.53 (205.93% Upside)
€23.53 (205.93% Upside)
Blogger Sentiment
Bullish
DE:MMQ Sentiment 100%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth $27.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
227.60%
12-Months-Change
Fundamentals
Return on Equity
-54.61%
Trailing 12-Months
Asset Growth
125.91%
Trailing 12-Months
Company Description
Mind Medicine
Mind Medicine Inc is a psychedelic medicine biotech company that discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The firm is having an approach towards developing the next generation of psychedelic inspired medicines and therapies.
---
MMQ Earnings Call
Q3 2024
0:00 / 0:00
---
MMQ Stock 12 Month Forecast
Average Price Target
€23.53
▲(205.93% Upside)
Technical Analysis
Mind Medicine
―
COMPASS Pathways
―
ATAI Life Sciences
―
Relmada Therapeutics
―
Cybin
―
Best Analysts Covering MMQ
1 Year
1 Year Success Rate
7/10 ratings generated profit
1 Year Average Return
+50.00%
reiterated a buy rating 7 days ago
Copying Brian Abrahams's trades and holding each position for 1 Year would result in 70.00% of your transactions generating a profit, with an average return of +50.00% per trade.
---